(AIM: SAR)

9 February 2011

SAREUM HOLDINGS PLC
(“Sareum” or the “Company”)

Statement re Share Price Movement

Sareum (AIM: SAR), the specialist cancer drug discovery business, has noted the recent significant rise in the Company’s share price, the volume of shares traded in the last two trading sessions and the bulletin board and press comments following the announcement made on 7 February 2011 with the headline “Research Update: Positive Leukaemia Model Study”.

The Company can confirm that it is not currently in advanced stages of discussion with a potential licencing partner and there can be no certainty that the announcement of these results will lead to a licencing agreement being entered into.

The Company can confirm that the results of the study have, in the ordinary course of business, been sent to potential licencing partners and the Company will be engaging with these partners to determine their interest in the data.

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements/Bidhi Bhoma

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce

020 7947 4350

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk